Evidence map›Paper›PMID 36573718›Full record

ArticleJournal of personalized medicine2022

The Comparative Superiority of SARS-CoV-2 Antibody Response in Different Immunization Scenarios.

Ourania S Kotsiou, Nikolaos Karakousis, Dimitrios Papagiannis, Elena Matsiatsiou, Dimitra Avgeri, Evangelos C Fradelos, Dimitra I Siachpazidou, Garifallia Perlepe, Angeliki Miziou, Athanasios Kyritsis and 4 more

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ourania S KotsiouFaculty of Nursing, School of Health Sciences, University of Thessaly, GAIOPOLIS, 41110 Larissa, Greece.ORCID 0000-0001-5219-6971
Nikolaos KarakousisPrimary Healthcare, Internal Medicine Department, Amarousion, 15125 Athens, Greece.ORCID 0000-0003-4882-7042
Dimitrios PapagiannisPublic Health & Vaccines Lab, Department of Nursing, School of Health Sciences, University of Thessaly, GAIOPOLIS, 41110 Larissa, Greece.
Elena MatsiatsiouFaculty of Nursing, School of Health Sciences, University of Thessaly, GAIOPOLIS, 41110 Larissa, Greece.
Dimitra AvgeriFaculty of Nursing, School of Health Sciences, University of Thessaly, GAIOPOLIS, 41110 Larissa, Greece.
Evangelos C FradelosFaculty of Nursing, School of Health Sciences, University of Thessaly, GAIOPOLIS, 41110 Larissa, Greece.ORCID 0000-0003-0244-9760
Dimitra I SiachpazidouDepartment of Respiratory Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, BIOPOLIS, 41110 Larissa, Greece.ORCID 0000-0002-7688-8072
Garifallia PerlepeDepartment of Respiratory Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, BIOPOLIS, 41110 Larissa, Greece.ORCID 0000-0002-9546-6780
Angeliki MiziouDepartment of Respiratory Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, BIOPOLIS, 41110 Larissa, Greece.
Athanasios KyritsisDepartment of Respiratory Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, BIOPOLIS, 41110 Larissa, Greece.
Eudoxia GogouDepartment of Respiratory Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, BIOPOLIS, 41110 Larissa, Greece.
George D VavougiosDepartment of Respiratory Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, BIOPOLIS, 41110 Larissa, Greece.ORCID 0000-0002-0413-4028
George KalantzisDepartment of Respiratory Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, BIOPOLIS, 41110 Larissa, Greece.
Konstantinos I GourgoulianisDepartment of Respiratory Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, BIOPOLIS, 41110 Larissa, Greece.ORCID 0000-0001-9541-1010

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Both SARS-CoV-2 infection and/or vaccination result in the production of SARS-CoV-2 antibodies. We aimed to compare the antibody titers against SARS-CoV-2 in different scenarios for antibody production. Methods: A surveillance program was conducted in the municipality of Deskati in January 2022. Antibody titers were obtained from 145 participants while parallel recording their infection and/or vaccination history. The SARS-CoV-2 IgG II Quant method (Architect, Abbott, IL, USA) was used for antibody testing. Results: Advanced age (>56 years old) was associated with higher antibody titers. No significant differences were detected in antibody titers among genders, BMI, smoking status, comorbidities, vaccine brands, and months after the last dose. Hospitalization length and re-infection were predictors of antibody titers. The individuals who were fully or partially vaccinated and were also double infected had the highest antibody levels (25,017 ± 1500 AU/mL), followed by people who were fully vaccinated (20,647 ± 500 AU/mL) or/partially (15,808 ± 1800 AU/mL) vaccinated and were infected once. People who were only vaccinated had lower levels of antibodies (9946 ± 300 AU/mL), while the lowest levels among all groups were found in individuals who had only been infected (1124 ± 200 AU/mL). Conclusions: Every hit (infection or vaccination) gives an additional boost to immunization status.

Indexed as

antibodyCOVID-19immunizationinfectionvaccination

Identifiers

PMID36573718
PMCPMC9698429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.